Beximco Pharmaceuticals
Seoul, South Korea· Est.
South Korean biotech leveraging AI‑driven small‑molecule drugs for metabolic and infectious diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
South Korean biotech leveraging AI‑driven small‑molecule drugs for metabolic and infectious diseases.
Metabolic DiseasesInfectious Diseases
Technology Platform
A proprietary medicinal chemistry platform that integrates high‑throughput synthesis with AI‑driven predictive modeling to accelerate small‑molecule discovery and optimization.
Opportunities
Leveraging AI‑driven chemistry to shorten development timelines positions Beximco to capture market share in fast‑growing metabolic and antiviral drug segments.
Risk Factors
Early‑stage pipeline attrition and dependence on external CMO capacity could delay clinical progress and increase costs.
Competitive Landscape
Competes with Korean and global small‑molecule developers; differentiation stems from its integrated AI‑chemistry platform and focus on oral therapeutics for metabolic and infectious diseases.